Drug intelligence / Profile preview

N-Q11

Development stage: Preclinical
Lead developer: Neurocarrus
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intramuscular

Overview

N-Q11 is an engineered recombinant protein biologic developed by Neurocarrus for the treatment of migraine. It is designed to selectively target nociceptors (pain-sensing neurons) and inhibit the release of neurotransmitters such as Calcitonin Gene-Related Peptide (CGRP) and glutamate. The molecule functions by cleaving the Synaptosomal-associated protein 25 (SNAP-25), a component of the SNARE complex required for synaptic vesicle exocytosis. By utilizing a modified botulinum toxin-based delivery system, N-Q11 aims to provide long-lasting pain relief with reduced systemic toxicity compared to traditional botulinum toxin therapies.

Targets

SNAP25 (Synaptosome-associated protein 25)

Beyond the preview

Go deeper on N-Q11.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N-Q11.

Explore the full profile